Fungi, once noninfectious, have evolved into opportunistic pathogens, increasing the frequency of skin fungal infections, affecting 20-25% of the human population, especially immunocompromised individuals. Types include superficial, cutaneous, and subcutaneous fungal infections. Antifungal drugs are used to treat skin fungal infections, but they can cause burning, erythema, and stinging. Hydrophilic, lipophilic, and nanocarrier methods are being explored for topical delivery. Vesicular nanocarrier systems effectively treat skin fungal disorders, but excessive penetration could harm targeted therapy. Further investigation is needed for safety, therapeutic potency, and scaling-up approaches. Topical drug administration is effective for treating skin-related ailments, but direct skin contact can cause irritation. The USFDA recommends using GRASS-certified excipients, and evaluating skin irritation potential is crucial for risk evaluation. Nanocarriers could improve antifungal medication delivery for fungal infections, overcoming challenges in traditional treatments. Further research should address clinical application obstacles. Researchers are exploring nanocarriers like nanoliposomes, polymer nanoparticles, solid lipid nanoparticles, and dendrimers to improve encapsulated medication treatments. Nanocarriers can contain hydrophilic and hydrophobic medications, with smaller particles having optimal penetration into deeper skin layers